Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus
The protein has a calculated MW of 48.4 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human IL-2 R alpha Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human IL-2 R alpha Protein, Fc Tag (Cat. No. ILA-H5251) is more than 90% and the molecular weight of this protein is around 102-124 kDa verified by SEC-MALS.
Immobilized Human IL-2 R alpha Protein, Fc Tag (Cat. No. ILA-H5251) at 2 μg/mL (100 μL/well) can bind Human IL-2, Tag Free with a linear range of 0.4-3 ng/mL (QC tested).
Human IL-2 R alpha Protein, Fc Tag (Cat. No. ILA-H5251) captured on CM5 chip via anti-human IgG Fc antibody can bind Human IL-2, Tag Free with an affinity constant of 10.1 nM as determined in a SPR assay (Biacore T200) (Routinely tested)
Loaded Human IL-2 R alpha, Fc Tag (Cat. No. ILA-H5251) on Protein A Biosensor, can bind Human IL-2, Tag Free with an affinity constant of 43.2 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Daclizumab biosimilar (Shanghai CP Guojian) | Approved | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 健尼哌 | Mainland China | Rejection of renal transplantation | null | 2011-01-12 | Rejection of renal transplantation | Details | |
Daclizumab | R-35; BIIB-019; RO-247375 | Approved | Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd | Zinbryta, Zenapax | United States | Rejection of organ transplantation | F. Hoffmann-La Roche Ag | 1997-12-10 | Rejection of organ transplantation; Behcet Syndrome; Melanoma; Leukemia, T-Cell; Lymphoma; Rejection in heart transplantation; Thrombocytopenia; Uveitis; Iritis; Asthma; Colitis, Ulcerative; Uveitis, Anterior; Anemia, Aplastic; Breast Neoplasms; Psoriasis; Retinal Diseases; Multiple Sclerosis, Relapsing-Remitting; Carcinoma, Ductal; Radiation Injuries; Arthritis, Juvenile; Multiple Sclerosis; Red-Cell Aplasia, Pure; Anemia, Diamond-Blackfan; Myelodysplastic Syndromes; HTLV-I Infections; Inflammatory Bowel Diseases; Gastrointestinal Diseases; Leukemia; Diabetes Mellitus, Type 1; Granulomatosis with Polyangiitis; HIV Infections | Details |
Basiliximab | CHT-25; chRFT5; CHI-621; SDZ-CHI-621 | Approved | Novartis Pharma Ag | 舒莱, Simulect | United States | Rejection of organ transplantation | Novartis Pharma Ag | 1998-05-12 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Uveitis; Lymphoma, Non-Hodgkin; Emphysema; Pulmonary Disease, Chronic Obstructive; Primary Myelofibrosis; Colitis, Ulcerative; Anemia, Aplastic; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Hodgkin Disease; Hemoglobinuria, Paroxysmal; Keratoplasty rejection; Cytokine Release Syndrome; Leukemia, Myelogenous, Chronic | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Nemvaleukin alfa | RDB-1419; RDB-1450; ALKS-4230 | Phase 3 Clinical | Alkermes Plc | Ovarian Neoplasms; Solid tumours; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma | Details |
Basiliximab biobetter (Mabtech/Sorrento) | STI-003 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Autoimmune Diseases | Details |
PT-101 | PT-101; MK-6194; PT101 | Phase 2 Clinical | Pandion Therapeutics | Lupus Erythematosus, Systemic; Colitis, Ulcerative; Vitiligo; Dermatitis, Atopic | Details |
LMB-2 | LMB-2; LMB-2a | Phase 2 Clinical | National Cancer Institute | Leukemia; Skin Melanoma; Leukemia, Hairy Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Skin Neoplasms; Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, T-Cell | Details |
Camidanlumab tesirine | ADCT-301 | Phase 2 Clinical | Adc Therapeutics Sa, Genmab A/S | Myelodysplastic Syndromes; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Myeloproliferative Disorders; Pancreatic Neoplasms; Hodgkin Disease; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck | Details |
Humanized Anti-CD25 Antibody(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Graft vs Host Disease | Details | |
90Y Basiliximab | Phase 2 Clinical | City Of Hope National Medical Center | Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous | Details | |
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 | HuMikβ1-1 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, National Institutes Of Health | Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic | Details |
Vopikitug | RO-7296682; RG-6292 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
BA-1106 | TS-1904; BA-1106; RR-102 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
XmAb-564 | XmAb-564; XmAb564; XmAb-27564 | Phase 1 Clinical | Xencor Inc | Autoimmune Diseases; Psoriasis; Dermatitis, Atopic | Details |
IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
9MW-3911 | 9MW3911; 9MW-3911 | Phase 1 Clinical | Nanjing Nuo Aixin Biotechnology Co Ltd | Neoplasms | Details |
In 111-DOTA-Basiliximab | Phase 1 Clinical | City Of Hope National Medical Center | Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
BMS-986326 | BMS-986326 | Phase 1 Clinical | Bristol-Myers Squibb Company | Lupus Vulgaris; Dermatitis, Atopic | Details |
This web search service is supported by Google Inc.